EWA
FATE icon

Evolution Wealth Advisors’s Fate Therapeutics FATE Stock Holding History

Evolution Wealth Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-48
Closed -$3K – 324
2021
Q3 		$3K Sell
48
-72
-60% -$5.65K ﹤0.01% 604
2021
Q2 		$10K Sell
120
-12
-9% -$967 ﹤0.01% 406
2021
Q1 		$11K Sell
132
-73
-36% -$7K ﹤0.01% 399
2020
Q4 		$19K Buy
+205
New +$12.7K ﹤0.01% 273

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Evolution Wealth Advisors's FATE Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 48 shares — an estimated $3K sold.

Evolution Wealth Advisors first reported a position in FATE in Q4 2020 and held it in 4 quarters. The position peaked at $19K in Q4 2020. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

  • Evolution Wealth Advisors reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Evolution Wealth Advisors sold 48 Fate Therapeutics shares in Q4 2021, an estimated $3K.
  • Evolution Wealth Advisors first reported a position in Fate Therapeutics in Q4 2020 and held it in 4 quarters.
  • Evolution Wealth Advisors's Fate Therapeutics position peaked at $19K in Q4 2020.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.